Clinical Trial Update: Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation [Phase 4]

View source ↗

Summary

Phase 4 pilot study investigating strategies to mitigate GI symptoms associated with dimethyl fumarate in Relapsing-remitting multiple sclerosis. The trial was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Rocky Mountain MS Research Group, LLC | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: TERMINATED | Results posted: 2017-01-06